CHRISTOPHER CAUSEY - 02 Jan 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
Director
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Issuer symbol
UTHR
Transactions as of
02 Jan 2026
Net transactions value
-$380,255
Form type
4
Filing time
05 Jan 2026, 16:59:29 UTC
Previous filing
04 Nov 2025
Next filing
06 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CAUSEY CHRISTOPHER Director C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING /s/ John S. Hess, Jr. under Power of Attorney 05 Jan 2026 0001237334

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $119,760 +1,000 +24% $119.76 5,190 02 Jan 2026 Direct F1
transaction UTHR Common Stock Sale $500,015 -1,000 -19% $500.01 4,190 02 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Option Options Exercise $0 -1,000 -11% $0.000000 8,320 02 Jan 2026 Common Stock 1,000 $119.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 30, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $500.00 to $500.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.